• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

    3/12/24 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RIGL alert in real time by email

    SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background.

    "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge complements our existing leadership team and supports the growth of Rigel's clinical portfolio," said Raul Rodriguez, Rigel's president and CEO. "We welcome Dr. Rojkjaer to the team during an exciting time for Rigel's clinical programs, including our recently announced collaborations with MD Anderson and CONNECT to expand the evaluation of olutasidenib in a broad range of IDH1-mutant cancers and our ongoing Phase 1b trial of R289 being developed for patients with lower-risk myeloid dysplastic syndrome (LR-MDS)." 

    "I am thrilled to join the leadership team at this important time for Rigel as its commercial portfolio and development pipeline of hematology and oncology assets are generating significant momentum," said Dr. Rojkjaer. "The compelling science underlying Rigel's programs, coupled with their commercial expertise and focus, position the company to bring potential new therapies to patient populations with significant unmet need."

    Prior to joining Rigel, Dr. Rojkjaer held several leadership positions in clinical development and medical affairs at biotechnology and global pharmaceutical companies, having most recently served as Chief Medical Officer of Sangamo Therapeutics. Prior to Sangamo, she held the role of Chief Medical Officer at both Viracta Therapeutics and Nordic Nanovector, where she led clinical and regulatory strategies across a broad range of hematology and oncology programs. Dr. Rojkjaer also served as Global Clinical Program Head at Novartis Pharmaceuticals where she led development and supported the regulatory approval of Rydapt®, a multikinase inhibitor for the treatment of FLT3 mutation-positive AML. Other previous roles include Chief Medical Officer at Molecular Partners, Vice President, Head of Clinical Development at MorphoSys AG, and Director of Clinical Development and Head, Global Medical Affairs, Biopharmaceuticals at Novo Nordisk. Dr. Rojkjaer holds a Doctor of Medicine degree from the University of Toronto, where she also completed her internal medicine and hematology fellowships.

    About Rigel

    Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

    Forward-Looking Statements

    This press release contains forward-looking statements relating to, among other things, Rigel's ability to further develop its clinical stage programs and Rigel's partnering effort, including the progress of the Phase 1b clinical trial of R289 for the treatment of lower-risk myeloid dysplastic syndrome, the evaluation of olutasidenib in a broad range of IDH1-mutant cancers with the CONNECT and MD Anderson collaborations, and the commercialization of our products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward -looking statements can be identified by words such as "potential", "may", "expects", "will" and similar expressions in reference to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations, and assumptions and hence they inherently involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of fostamatinib or olutasidenib; risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding Rigel's products; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that Rigel's products may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10K for the year ended 2023 and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

    Contact for Investors & Media:

    Investors:

    Rigel Pharmaceuticals, Inc.

    650.624.1232

    [email protected] 

    Media:

    David Rosen

    Argot Partners

    212.600.1902

    [email protected]

    Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-announces-appointment-of-lisa-rojkjaer-md-as-chief-medical-officer-302086086.html

    SOURCE Rigel Pharmaceuticals, Inc.

    Get the next $RIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RIGL

    DatePrice TargetRatingAnalyst
    4/3/2023$2.00Neutral
    Piper Sandler
    6/9/2022Buy → Neutral
    Citigroup
    6/8/2022$7.00 → $1.00Overweight → Neutral
    Piper Sandler
    6/8/2022$6.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    3/23/2022$4.00Neutral
    B. Riley Securities
    More analyst ratings

    $RIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 5:18:08 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 3:33:13 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

      SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/8/24 9:33:38 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Financials

    Live finance-specific insights

    See more
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs

      4/29/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 millionR289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast sch

      3/4/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    SEC Filings

    See more
    • Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/23/25 4:01:19 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:23:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rigel Pharmaceuticals Inc.

      10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:05:42 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wasman Jane was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4)

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      5/28/25 5:27:41 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ali-Jackson Kamil was granted 2,500 shares, increasing direct ownership by 36% to 9,375 units (SEC Form 4)

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      5/28/25 5:27:31 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4)

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      5/28/25 5:27:19 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

      3/10/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp

      3/12/24 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $RIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Rigel Pharma with a new price target

      Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00

      4/3/23 9:11:21 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Citigroup

      Citigroup downgraded Rigel Pharma from Buy to Neutral

      6/9/22 7:22:28 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously

      6/8/22 1:49:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rigel to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY. To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotec

      5/28/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

      Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors  Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AMLSOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. The ASCO Annual Meeting is being held in Chicago, Illinois and virtually from May 30 to June 3, 2025. The EHA2025 Congress is

      5/22/25 5:20:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care